TobyMaherMD
Pulmonology • Los Angeles, CAInterstitial Lung Diseases
Professor of Clinical Medicine and Director of Interstitial Lung Disease
Dr. Maher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1520 San Pablo St
Ste 1000
Los Angeles, CA 90033Phone+1 323-442-5100
Summary
- I am a pulmonologist specializing in the diagnosis and treatment of interstitial lung diseases including; idiopathic pulmonary fibrosis, sarcoidosis, lung disease related to connective tissue diseases and rheumatoid arthritis, chronic hypersensitivity pneumonitis, histiocytosis and LAM.
Education & Training
University of Southampton Faculty of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 2020 - 2026
Clinical Trials
- Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17
Roles: Contact
- LYT-100 in Post-acute COVID-19 Respiratory Disease Start of enrollment: 2020 Dec 11
- Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis Start of enrollment: 2022 Sep 08
- Join now to see all
Publications & Presentations
PubMed
- Efficacy and Safety of Admilparant, an LPAAntagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.Tamera J Corte, Juergen Behr, Vincent Cottin, Marilyn K Glassberg, Michael Kreuter
American Journal of Respiratory and Critical Care Medicine. 2024-10-11 - Competing Causes of Death in Idiopathic Pulmonary Fibrosis.Ashwatha Thenappan, Toby M Maher, Leda Yazbeck, R Gisli Jenkins, Simon R Johnson
American Journal of Respiratory and Critical Care Medicine. 2024-10-01 - The future of clinical trials in idiopathic pulmonary fibrosis.Paolo Spagnolo, Toby M Maher
Current Opinion in Pulmonary Medicine. 2024-09-01
Press Mentions
PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b TrialDecember 16th, 2024- Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AINovember 12th, 2024
- AI-Driven Drug Discovery Achieves Milestone with Insilico Medicine’s Phase IIa Success in Treating Pulmonary FibrosisSeptember 26th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
